Obesity
|
OPPORTUNITY NUMBER |
OPPORTUNITY TITLE |
AGENCY NAME |
POSTED DATE |
CLOSE DATE |
|---|---|---|---|---|
|
Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed) |
HHS-NIH11 | 08/24/2023 |
01/07/2027 |
|
|
Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional) |
HHS-NIH11 | 08/23/2023 |
01/07/2027 |
|
|
Fiscal Year (FY) 2024 AmeriCorps State and National Competitive Grants |
AC | 08/18/2023 |
01/04/2024 |
|
|
Early-Stage Preclinical Validation of Therapeutic Leads for Diseases of Interest to the NIDDK (R01 Clinical Trial Not Allowed) |
HHS-NIH11 | 02/04/2022 |
01/07/2025 |
|
|
Time-Sensitive Obesity Policy and Program Evaluation (R01 Clinical Trial Not Allowed) |
HHS-NIH11 | 08/11/2021 |
09/10/2024 |